Viral vector company Sirion opening Boston office; Jon Rees steps down at OBN;

@FierceBiotech: With IPO in mind, cancer player CytomX steps up with a $70M round. News | Follow @FierceBiotech

@JohnCFierce: Deputy at China agency that probed GSK arrested for corruption, report says. FiercePharmaAsia article | Follow @JohnCFierce

@DamianFierce: And hey $AGN's spending $2.1B on $KYTH and its chin-fat-reducing injection. Release | Follow @DamianFierce

> The viral vector platform company Sirion, based in Munich, plans to open an office in the Boston/Cambridge biotech hub. Release

> Jon Rees is stepping down as executive director of OBN, a biotech trade group that sponsors the annual BioTrinity meeting in the U.K. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Sweden's Elekta hits Varian Medical with patent suit over cancer care devices. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Alcon gets CE mark to sell new intraocular lens in Europe. Report | Follow @VarunSaxena2

@EmilyWFierce: "You're a regulator. Regulate." NYT story | Follow @EmilyWFierce

> HeartWare, hit with its fifth Class 1 recall of 2015, will replace defective blood pump controllers. Story

> Irish startup Neuravi raises $21M to get stroke stent retrieval device through pivotal trial. News

Pharma News

@FiercePharma: Why The Trans Fat Ban and Labels On Salt And Soda Won't Make Us Healthier. More from Forbes | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Bad news for AbbVie: Humira copies expected to rack up biggest biosim sales. Article | Follow @CarlyHFierce

> FDA balks on generic Concerta as Mallinckrodt, Actavis meds gobble up market. Story

> Allergan extends deal spree with $2.1B Kythera buyout. News

Biotech Research News

> New tool for brown fat drug development research. Item

> Harvard team transplants circadian wiring, pointing to new drug applications. More

> Scripps spotlights PPARy inhibitor as a potential drug for bone loss. Article

> Preclinical trials show ALK1 inhibitor dalantercept may prevent metastasis. Story

> New study will test feds' support for anti-aging drug research. Report

Diagnostics News

> Welch Allyn sells out to Hill-Rom for $2.05B. Item

> OraSure to receive up to $10M from feds to develop rapid Ebola test. More

> Ariosa Diagnostics scores CE mark for prenatal test software. News

> Sequenom slapped down in prenatal testing patent battle with Ariosa. Story

> Illumina teams up with Chinese genomics firm for noninvasive prenatal test development. Article

Pharma Marketing News

> Taking the guesswork out of sales, predictive analytics could lead way to improved pharma rep decisions. Article

> Astellas, Medivation to amp up unbranded Xtandi marketing for pre-chemo use. Report

> Good news for drug reps: Pay is growing again. Bad? Biotech outclasses pharma by 36%. More

> Ready to prescribe PCSK9 meds? Doctors say yes, yes, yes. Story

> Shire's Vyvanse could bag another lucrative new market in menopausal women. Article

 

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.